

Special Issue

ROS-Mediated Nano Drug Delivery for Antitumor Therapy

Message from the Guest Editors

We are pleased to invite you to submit original research papers and reviews in the field of ROS-mediated antitumor nanomedicine. ROS are a class of chemically reactive small molecules containing oxygen. Compared with normal cells, tumor cells generally have higher concentrations of ROS and are more susceptible to oxidative stress-induced cell death, which makes ROS-based therapies inherently tumor-selective. ROS-mediated tumor oxidation therapy and ROS-responsive drug delivery system are two key components of ROS-mediated therapies. Recently, ROS has emerged as an innovative and unique treatment mode as it can not only directly kill tumor cells but also induce immunogenic cell death (ICD) to activate the body's immune responses. In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: ROS-mediated tumor oxidation therapy/combination therapy, ROS-responsive anti-tumor drug delivery system, ROS-mediated tumor immunotherapy, and other related areas. We look forward to receiving your contributions.

Guest Editors

Dr. Yanjuan Huang

School of Pharmaceutical Sciences, Sun Yat-Sen University,
Guangzhou 510006, China

Dr. Xiaoyu Xu

Department of Pharmaceutics, School of Pharmaceutical Sciences,
Sun Yat-Sen University, Guangzhou 510006, China

Deadline for manuscript submissions

28 August 2026



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 6.9
CiteScore 12.5
Indexed in PubMed



mdpi.com/si/215213

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 6.9
CiteScore 12.5
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceuticals and biopharmaceuticals. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, William Levine Hall, Room 225C, 160 Frelinghuysen Road, Piscataway, NJ 08854-8020, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.3 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2026).